Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 9, 2003. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from employee trust transactions and retirement plan movements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction volumes and pricing related to employee compensation plans.
- Share Transactions: Various transfers and sales of Ordinary Shares occurred between June 5 and June 9, 2003.
- Transaction Prices: Ordinary Shares were sold at £12.75 per share. ADRs were transacted at average prices of $42.30 and $41.90.
- ADR Holdings: The GlaxoSmithKline US Retirement Savings Plan held between 18,659,243 and 18,729,853 ADRs during the reporting window.
Material Changes
The filing reports specific movements in share holdings within employee trusts and retirement plans rather than operational changes:
- June 5, 2003: The GSK Trust transferred 4,932 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- June 6, 2003: The US Retirement Savings Plan's ADR holdings decreased by 70,610 shares (from 18,729,853 to 18,659,243).
- June 6, 2003: The GSK Trust sold 4,539 Ordinary Shares on behalf of a participant in the Glaxo Wellcome 1999 Long Term Incentive Plan.
- June 9, 2003: The GSK Trust transferred 6,505 Ordinary Shares to a participant in the Glaxo Wellcome 1999 Long Term Incentive Plan.
- June 9, 2003: The US Retirement Savings Plan's ADR holdings increased by 55,664 shares (from 18,659,243 to 18,714,907).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a regulatory disclosure of director interests and does not contain forward-looking statements or risk assessments.
Important Facts for Investors to Verify
- Directors Dr. J-P Garnier and Mr. J D Coombe hold indirect interests in shares held by the GSK Trust.
- Director Dr. J-P Garnier holds a potential interest in shares held by the GlaxoSmithKline US Retirement Savings Plan.
- Share price volatility is indicated by the fluctuation in ADR average prices ($42.30 to $41.90) over a three-day period.
- The filing confirms the company's compliance with reporting requirements for changes in director interests under the Securities Exchange Act of 1934.